

Giuseppe Murdaca, MD, PhD

Personal data

Birthdate and place: 05/08/1968, Genova, Italy
Married, 1 daughter
Present position: Associate Professor-Internal Medicine
Institution Address: Di.M.I.-University of Genova
Viale Benedetto XV, n. 6-16132 Genova, Italy
Telephone: +39-010-3537924
Fax: +39-010-5556950
e-mail: Giuseppe.Murdaca@unige.it

Education

1993 M.D. Degree, cum laude, University of Genova

Specialty certifications

1999 Allergology and Clinical Immunology, University of Genova
2003 PhD in Sciences and Space Engineering

Professional experience

1996-1999 Fellow- Allergology and Clinical Immunology
2006-2017 Assistant Professor-Internal Medicine
From 2017 Associate Professor-Internal Medicine

Membership

Italian Society of Immunology, Clinical Immunology and Allergy
Italian Society of Internal Medicine
Italian Society of Experimental Biology

Editor in Chief of the following scientific journals

From 2012 Journal of medical Cases (Section Editors)
From 2014 International Archives of Medicine (Chief editor in section of Immunology)
From 2015 Edorium™ Journal of Medicine
From 2015 Autoimmune Diseases and Therapeutic Approaches: Open Access
From 2015 International Journal of TROPICAL DISEASE & Health (Academic Editor)
From 2016 Journal of Immunization
From 2016 Journal of Novel Physiotherapies
From 2016 Asian Journal of Medicine and Health (Academic Editor)
From 2016 Archives of renal diseases and management

Component of the Editorial Board of many scientific journals

Research interest

Immunodeficiency
Autoimmunity
Neuro-endocrino-immunology
Pharmacogenomics
Vaccine and autoimmune diseases

Publications

Papers on peer reviewed journals: 109
Oral presentations and abstracts: 93

List of print publications in indexed journals

1. Zentilin P, Savarino V, Marabotto E, **Murdaca G**, Sulli A, Pizzorni C, Puppo F, Savarino E. Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. *Semin Arthritis Rheum*. 2017 in press. (IF: 4.498).
2. **Murdaca G**, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R, Mandich P, Puppo F. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. *Mod Rheumatol*. 2017Aug 24:1-15. (IF: 2.206).
3. **Murdaca G**, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. *Expert Opin Drug Saf*. Aug 4:1-7. (IF: 3.469).
4. **Murdaca G**, Lantieri F, Puppo F, Bezante GP, Balbi M. Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. *J Int Med Res*. 2016 Sep;44(1 suppl):85-89. (IF: 1.431).
5. Contini P, Puppo F, Canonica GW, **Murdaca G**, Ciprandi G. Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. *Hum Immunol*. 2016;77(12):1172-8. (IF: 2.127).
6. **Murdaca G.**, Contini P., Negrini S., Ciprandi G., Puppo F. Immunoregulatory Role of HLA-G in Allergic Diseases. *J Immunol Res*. 2016;2016:6865758. (IF: 2.812).
7. Negrini S, Pappalardo F, **Murdaca G**, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. *Clin Exp Med*. 2017;17(3):257-67. (IF: 2.959).
8. **Murdaca G.**, Contatore C., Gulli R., Mandich P., Puppo F. Genetic factors and Systemic Sclerosis. *Autoimmun Rev* 2016;15(5):427-32. (IF: 7.975).
9. **Murdaca G.**, Orsi A., Spanò S., Puppo F., Durando P., Icardi G., Ansaldi F. Vaccine-preventable infections in Systemic Lupus Erythematosus. *Hum Vaccin Immunother* 2016;12(3):632-43. (IF: 2.366).

10. **Murdaca G.**, Contini P., Cagnati P., Marengo S., Pieri G., Lantieri F., Picciotto A., Puppo F. Behavior of soluble HLA-A,-B,-C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon- α and ribavirin treatment: potential role as markers of response to antiviral therapy. *Clin Exp Med.* 2017;17(1):93-100. (IF: 2.959).
11. **Murdaca G.**, Spanò F., Contatore M., Guastalla A., Penza E., Magnani O., Puppo F. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? *Expert Opin Drug Saf* 2016;15(1):43-52. (IF: 3.469).
12. **Murdaca G.**, Russo R., Spanò F., Ferone D., Albertelli M., Schenone A., Contatore M., Guastalla A., De Bellis AM., Garibotto G., Puppo F. Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. *Arch Endocrinol Metab* 2015;59(6):554-8.. (IF: 0.844).
13. **Murdaca G.**, Spanò F., Contatore M., Guastalla A., Penza E., Magnani O., Puppo F. Infection risk associated with anti-TNF- α agents: a review. *Expert Opin Drug Saf* 14(4):571-82, 2015. (IF: 2.911).
14. **Murdaca G**, Gulli R, Spanò F, Mandich P, Puppo F. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? *Drug Dev Res* 75 Suppl 1:S7-S10, 2014. (IF: 0.734)
15. Gisoni P, **Murdaca G**. Seminars in research 2013: joint experiences using biologics in rheumatology and dermatology. *Drug Dev Res* 75 Suppl 1:S1-2, 2014. (IF: 0.734)
16. **Murdaca G**, Spanò F, Contatore M, Guastalla A, Magnani O, Puppo F. Pharmacogenetics of etanercept: role of TNF- α gene polymorphisms in improvement its efficacy. *Expert Opin Drug Metab Toxicol* 10(12):1703-10, 2014. (IF: 2.934)
17. **Murdaca G**, Spanò F, Contatore M, Guastalla A, Magnani O, Puppo F. Efficacy and safety of etanercept in chronic immune-mediated disease. *Expert Opin Drug Saf* 13(5):649-61, 2014. (IF: 2.911).
18. **Murdaca G**, Gulli R, Spanò F, Lantieri F, Burlando M, Parodi A, Mandich P, Puppo F. TNF- α gene polymorphisms: association with disease susceptibility and response to anti-TNF- α treatment in psoriatic arthritis. *J Invest Dermatol* 134(10):2503-9, 2014. (IF: 6.372).
19. **Murdaca G**, Spanò F, Contatore M, Guastalla A, Puppo F. The potential use of TNF- α inhibitors in Systemic Sclerosis. *Immunotherapy* 6(3):283-9, 2014. (IF: 2.393).
20. **Murdaca G**, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. *Expert Opin Drug Saf* 13(3):295-305, 2014. (IF: 2.911).
21. **Murdaca G**, Orsi A, Spanò F, Puppo F, Durando D, Icardi G, Ansaldi F. Influenza and pneumococcal vaccination of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. *Autoimmun Rev* 13(2):75-84, 2014. (IF: 7.975).
22. **Murdaca G**, Spanò F, Puppo F. Use of leflunomide plus TNF- α inhibitors in rheumatoid arthritis. *Expert Opin Drug Saf* 12(6):801-4, 2013. (IF: 2.621).

23. **Murdaca G**, Spanò F, Puppo F. Pharmacogenetics: reality or dream in predicting the response to TNF- α inhibitor treatment? *J Genet Syndr Gene Ther* 2013;S3: 007.
24. **Murdaca G**, Spanò F, Puppo F. Long term treatment of Rheumatoid Arthritis with Adalimumab. *Open Access Rheumatology: Research and Reviews* 5:43–9, 2013.
25. Boccardo F, Fulcheri E, Villa G, Molinari L, Campisi C, Dessalvi S, **Murdaca G**, Campisi C, Santi PL, Parodi A, Puppo F, Campisi C. Lymphatic Microsurgery to Treat Lymphedema: Techniques and Indications for Better Results. *Ann Plast Surg* 71(2):191-5, 2013. (IF: 1.318).
26. **Murdaca G.**, Spanò F., Cagnati P., Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF- α inhibitors. *Redox Rep* 18(3):95-9, 2013. (IF: 1.732).
27. Fenoglio D., Traverso P., Parodi A., Tomasello L., Negrini S., Kalli F., Battaglia F., Ferrera F., Sciallero S., **Murdaca G.**, Setti M., Sobrero A., Boccardo F., Cittadini G., Puppo F., Criscuolo D., Carmignani G., Indiveri F., Filaci G. A Multi-Peptide, Dual-Adjuvant Telomerase Vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. *Cancer Immunol Immunother* 62(6):1041-52, 2013. (IF: 3.701).
28. **Murdaca G.**, Spanò F., Puppo F. Selective TNF alpha inhibitor-induced injection site reactions. *Expert Opin Drug Saf* 12(2):187-93, 2013. (IF: 3.015).
29. **Murdaca G.**, Spanò F., Miglino M., Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. *Immunotherapy* 5(2):113-5, 2013. (IF: 2.393).
30. **Murdaca G.**, Colombo BM., Cagnati P., Gulli R., Spanò F., Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. *Atherosclerosis* 224:309-17,2012. (IF: 4.086).
31. Ansaldi F., Valle L., de Florentiis D., Parodi V., **Murdaca G.**, Bruzzone BM., Durando P., Setti M., Icardi G. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. *Hum Vaccin Immunother* 8(8): 1048-52, 2012. (IF: 2.042).
32. **Murdaca G.**, Colombo BM., Contini P., Puppo F. Determination of lymphotoxin- α levels in patients with psoriatic arthritis undergoing etanercept treatment. *J Interferon Cytokine Res* 32(6):277-9, 2012. (IF: 3.063).
33. **Murdaca G.**, Colombo BM., Cagnati P., Gulli R., Spanò F., Puppo F. Update upon efficacy and safety of TNF- α inhibitors. *Expert Opin Drug Saf* 11(1):1-5, 2012. (IF: 2.645).
34. **Murdaca G.**, Cagnati P., Gulli R., Spanò F., Puppo F., Campisi C., Boccardo F. Current views on diagnostic approach and treatment of lymphedema. *Am J Med* 125(2):134-40, 2012. (IF: 5.115).
35. Campisi C, Witte MH, Fulcheri E, Campisi C, Bellini C, Villa G, Campisi C, Santi PL, Parodi A, **Murdaca G**, Puppo F, Boccardo F. General surgery, translational lymphology and lymphatic surgery. *Int Angiol* 30(6):504-21, 2011. (IF: 0.993).

36. **Murdaca G.**, Colombo BM., Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. *Autoimmun Rev* 11(1):56-60, 2011. (IF: 6.556).
37. **Murdaca G.**, Contini P., Setti S., Cagnati P., Spanò F., Lantieri F., Puppo F. Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment. *Human Immunology* 72:712-6, 2011. (IF: 2.550).
38. **Murdaca G.**, Colombo BM., Puppo F. Adalimumab in the treatment of immune-mediated diseases: an update on old and recent indications. *Drugs Today (Barc)* 47(1):277-88, 2011. (IF: 1.588).
39. **Murdaca G.**, Colombo BM., Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. *Intern Emerg Med* 6(6):487-95,2011. (IF: 2.139).
40. Boccardo F., Campisi C., **Murdaca G.**, Benatti E., Boccardo C., Puppo F., Campisi C. Prevention of lymphatic injuries in surgery. *Microsurgery* 30(4):261-5, 2010. (IF: 1.244).
41. Cagnati P., Colombo BM., Gulli R., Russo R., Boccardo F., Campisi C., Puppo F., **Murdaca G.** Nocturia: an uncommon presentation of lower limb lymphedema. *Am J Med* 123(3):e3-4, 2010. (IF: 5.105).
42. di Poggio MB., **Murdaca G.**, Puppo F., Primavera A. Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. *Semin Arthritis Rheum* 40(3):e9-10, 2010. (IF: 4.379)
43. **Murdaca G.**, Colombo BM., Barabino G., Caiti M., Cagnati P., Puppo F. Anti-tumour necrosis factor- α treatment with infliximab for disseminated granuloma annulare. *Am J Clin Dermatol* 11(6):437-9, 2010. (IF: 1.554).
44. **Murdaca G.**, Contini P., Setti M., Cagnati P., Lantieri F., Indiveri F., Puppo F. Behavior of non-classical soluble HLA class G antigens in Human Immunodeficiency Virus 1-infected patients before and after HAART: comparison with classical soluble HLA -A, -B, -C antigens and potential role in immune-reconstitution. *Clin Immunol* 133:238-44, 2009. (IF: 3.606).
45. **Murdaca G.**, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events.. *Int J Immunopathol Pharmacol* 22(3):557-65, 2009. (IF: 2.793).
46. Ciprandi G., Fenoglio D., De Amici M., Marseglia G., **Murdaca G.**, Di Gioacchino M. Serum IL-17 after one course of sublingual immunotherapy in allergic rhinitis to birch. *European Journal of Inflammation* 7(1):49-51, 2009. (IF: 2).
47. Ciprandi G., De Amici M., **Murdaca G.**, Fenoglio D., Ricciardolo F., Marseglia G., Tosca M. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. *Allergy* 64(9):1375-8, 2009. (IF: 6.2).
48. Ciprandi G., De Amici M., Tosca M., Negrini S., **Murdaca G.**, Marseglia GL. Two year sublingual immunotherapy affects serum leptin. *Int Immunopharmacol* 9(10):1244-6, 2009. (IF: 2).

49. Ciprandi G., Contini P., **Murdaca G.**, DeAmici M., Gallina AM., Puppo F. Soluble serum HLA-G and HLA-A,-B,-C molecules in patients with seasonal allergic rhinitis exposed to pollens. *Int Immunopharmacol* 9(9):1058-62, 2009. (IF: 2).
50. Fenoglio D., Poggi A., Castellani S., Battaglia F., Ferrera A., Setti M., **Murdaca G.**, Zocchi MR. V δ 1 T lymphocytes producing IFN- γ and IL-17 are expanded in HIV-1 infected patients and respond to *Candida albicans*. *Blood* 113(26):6611-8, 2009. (IF:10.896).
51. Boccardo FM., Ansaldi F., Bellini C., Accogli S., Taddei G., **Murdaca G.**, Campisi CC., Villa G., Icardi G., Durando P., Puppo F., Campisi C. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. *Lymphology* 42(1):1-9, 2009. (IF: 0.778).
52. Ciprandi G., Contini P., **Murdaca G.**, Gallina A.M., Puppo F. Soluble HLA-G molecule in patients with perennial allergic rhinitis. *Int Arch Allergy Immunol* 150(3):278-281, 2009. (IF:2.2).
53. Bezante GP., Briatore L., Rollando D., Maggi D., Setti M., Ghio M., Agosti S., **Murdaca G.**, Balbi M., Barsotti A., Cordera R. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage. *Nutr Metab Cardiovasc Dis* 19(4):277-82, 2009. (IF: 3.174).
54. Ciprandi G., Contini P., Pistorio A., **Murdaca G.**, Puppo F. Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. *Int Immunopharmacol* 9:253-7, 2009. (IF: 2).
55. Ciprandi G., De Amici M., **Murdaca G.**, Filaci G., Fenoglio D., Marseglia GL. Adipokines and sublingual immunotherapy: preliminary report. *Hum Immunol* 70(1):73-8, 2009. (IF: 3).
56. Colombo BM., Cacciapaglia F., Puntoni M., **Murdaca G.**, Rossi E., Rodriguez G., Nobili F., Pisciotta L., Bertolini S., Moccetti T., Dentali F., Steidl L., Ciprandi G., Afeltra A., Indiveri F., Puppo F. Traditional and nontraditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). *Autoimmun Rev* 8(4):309-15, 2009. (IF: 3.862).
57. Ciprandi G., **Murdaca G.**, Colombo BM., De Amici M., Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. *Hum Immunol.* 69(8):510-2, 2008. (IF: 3).
58. **Murdaca G.**, Cagnati P., Gulli R., Caiti M., Boccardo F., Campisi C., Puppo F. Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. *J Rheumatol.* 35(11):2291-2, 2008. (IF: 3,151).
59. Ciprandi G., Colombo BM., Contini P., Cagnati P., Pistorio A. , Puppo F., **Murdaca G.** Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. *Allergy* 63(10):1335-8, 2008. (IF: 6.2).
60. Ciprandi G., De Amici M., **Murdaca G.**, Colombo BM., Quaglini S., Marseglia G., Di Gioacchino M. Serum IL-4 as a marker of immunological response to sublingual immunotherapy. *J Biol Regul Homeost Agents* 22(2):117-23, 2008.(IF:2.9).

61. Ciprandi G., Colombo BM., **Murdaca G.**, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. *Allergy* 63(7):945-6, 2008. (IF: 6.2).
62. Ciprandi G., **Murdaca G.**, Marseglia G., Colombo BM., Quaglini S., De Amici M. Serum adiponectin levels in patients with pollen-induced allergic rhinitis. *Int Immunopharmacol* 8(6):945-9, 2008. (IF: 2).
63. Colombo BM., **Murdaca G.**, Ciprandi G., Sormani MP. Body mass index in Th1 and Th2 diseases. *Immunol Lett* 117(1):119-20, 2008. (IF: 2.8).
64. Giovannetti A., Pierdominici M., Di Iorio A., Cianci R., **Murdaca G.**, Puppo F., Pandolfi F., Paganelli R. Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases. *Curr Pharm Des* 14(3):253-68, 2008. (IF: 4.868).
65. **Murdaca G.**, Contini P., Setti M., Cagnati P., Villa R., Lantieri F., Indiveri F., Puppo F. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome. *Human Immunology* 68: 894-900, 2007. (IF: 2.901).
66. **Murdaca G.**, Colombo BM., Spreccacenero B., Caiti M., Massa G., Picciotto A., Ceppa P., Puppo F. Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome. *Eur J Gastroenterol Hepatol* 19(10): 910-912, 2007. (IF: 1.830).
67. Colombo BM., **Murdaca G.**, Caiti M., Rodriguez G., Grassia L., Rossi E., Indiveri F, Puppo F. Intima-media thickness. A marker of accelerated atherosclerosis in women with Systemic Lupus Erythematosus. *Ann N Y Acad Sci* 1108: 121-126, 2007. (IF: 1.731).
68. **Murdaca G.**, Colombo BM., Caiti M., Cagnati P., Massa G., Puppo F. Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report. *Int J Cardiol* 117(1): e35-e36, 2007. (IF: 2.878).
69. Colombo BM., **Murdaca G.**, Spreccacenero B., Rodriguez G., Rossi E., Puppo F. Accelerated atherosclerosis in patients with Systemic Lupus Erythematosus. *It J Allergy Clin Immunol* 16: 105-108, 2006.
70. **Murdaca G.**, Costantini S., Villa R., Setti M., Puppo F., Indiveri F. A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. *Intern Emerg Med* 1 (1): 86-88, 2006.
71. Puppo F., **Murdaca G.**, Ghio M., Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. *Autoimmun Rev* 4: 537-541, 2005. (IF: 3.862).
72. McDermott JL., Martini I., Ferrari D., Bertolotti F., Giacomazzi C., **Murdaca G.**, Puppo F., Indiveri F., Varnier OE. Decay of Human Immunodeficiency Virus Type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. *J Clin Microbiol* 43: 5272-5274, 2005. (IF: 3.913).
73. Poggi A., Contini P., Catellani S., Setti M., **Murdaca G.**, Zocchi MR. Regulation of gammadelta T cell survival by soluble HLA-I: Involvement of CD8 and activating killer Ig-like receptors. *Eur J Immunol* 35: 2670-2678, 2005.(IF:4.832).

74. Filaci G., Rizzi M., Setti M., Fenoglio D., Fravega M., Basso M., Ansaldo G., Ceppa P., Borgonovo G., **Murdaca G.**, Ferrera F., Picciotto A., Fiocca R., Torre G., Indiveri F. Non-Antigen-Specific CD8+ T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. *Ann N Y Acad Sci* 1050: 115-123, 2005. (IF: 1.731).
75. Fogli M., Costa P., **Murdaca G.**, Setti M., Mingari MC., Moretta L., Moretta A., De Maria A. Significant NK cell activation is associated with decreased cytolytic function in peripheral blood of HIV-1 infected patients. *Eur J Immunol* 34(8): 2313-2321, 2004.(IF:4.832).
76. Poggi A., Carosio R., Fenoglio D., Brenci S., **Murdaca G.**, Setti M., Indiveri F., Scabini S., Ferrero E., Zocchi MR. Migration of V δ 1 and V δ 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1 infected patients: competition by HIV-1 TAT. *Blood* 103(6): 2205-2213, 2004. (Pubblicato online il 20/11/2003). (IF: 9.782).
77. **Murdaca G.**, Setti M., Brenci S., Fenoglio D., Lantieri P, Indiveri F., Puppo F. Modifications of immunological and neuro-endocrine parameters induced by antiorthostatic bed-rest in human healthy volunteers. *Minerva Med* 94(6): 363-378, 2003.
78. **Murdaca G.**, Setti M., Cittadini G., Gentile G., Menin A., Fiocca R., Gobbi M., Puppo F., Indiveri F. Sindrome mediastinica: presentazione clinica di linfoma. Descrizione di un caso di linfoma di Hodgkin e di un caso di linfoma non Hodgkin con analoga presentazione. *Ann Ital Med Int* 18(3): 170-181, 2003.
79. De Maria A., Fogli M., Costa P., **Murdaca G.**, Puppo F., Mavilio D., Moretta A., Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). *Eur J Immunol* 33(9):2410-2418 , 2003.(IF:4.832).
80. Costa P., Rusconi S., Fogli M., Mavilio D., **Murdaca G.**, Puppo F., Mingari M.C., Galli M., Moretta L., De Maria A. Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. *AIDS* 17(2): 257-260, 2003.(IF: 6.881).
81. Indiveri F., **Murdaca G.** Immunogenicity of erythropoietin and other growth factors. *Rev Clin Exp Hematol, Supplemento 1*: 7-11, 2002.
82. **Murdaca G.**, Campelli A., Setti M., Indiveri F., Puppo F. Complete remission of AIDS/KS after treatment with a combination of two NRTIs and one NNRTI. *AIDS* 16(2): 304-305, 2002. (Lettera) (IF: 6.881).
83. Basso M., Filaci G., Cutolo M., **Murdaca G.**, Derchi L., Gianrossi R., Ropolo F., Zentilin P., Sulli A., Puppo F., Indiveri F. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. *Ann Ital Med Int* 16(4): 233-239, 2001.
84. Filaci G., Cutolo M., Basso M., **Murdaca G.**, Derchi L., Gianrossi R., Ropolo F., Zentilin P., Sulli A., Puppo F., Indiveri F. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. *Rheumatology* 40(12): 1431-1432, 2001.(Lettera) (IF: 3.062).
85. Costa P., Rusconi S., Mavilio D., Fogli M., **Murdaca G.**, Pende D., Mingari M.C., Galli M., Moretta L. De Maria A. Differential disappearance of inhibitory natural killer cell receptors

during HAART and possibile impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. *AIDS* 15(8): 965-974, 2001.(IF: 6.881).

86. **Murdaca G.**, Setti M., Campelli A., Ghio M., Puppo F., Indiveri F. Utilizzo dell'Amfotericina B liposomiale nel trattamento della fase acuta e nella profilassi secondaria della leishmaniosi viscerale in un paziente HIV positivo. *Infez Med* 8(4): 241-244, 2000.
87. Borrelli P., Imperato A., **Murdaca G.**, Scudeletti M. Liposomal Amphotericin B as first line and secondary prophylactic treatment for Visceral Leishmaniasis in a patient infected with HIV. *Ann Ital Med Int* 15(2): 169-171, 2000.
88. Filaci G., Cutolo M., Scudeletti M., Castagneto C., Derchi L., Gianrossi R., Ropolo F., Zentilin P., Sulli A., **Murdaca G.**, Ghio M., Indiveri F., Puppo F. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. *Rheumatology* 38(10):992-996, 1999.(IF: 3.062).
89. Parodi M.N., Castagneto C., Filaci G., **Murdaca G.**, Puppo F., Indiveri F., Scudeletti M. Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. *Br J Rheumatol.* 36(2):244-250, 1997.(IF:3.062).

List of Publications as a Search Groups Member

1. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med.* 2015;12(3):e1001809. (IF: 14.000).
2. Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. *J Am Heart Assoc* 3(3):e000844, 2014.
3. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. *N Engl J Med* 361(16):1548-59, 2009. (IF: 50.017).
4. Saracino A., Gianotti N., Marangi M., Cibelli DC., Galli A., Punzi G., Monno L., Lazzarin A., Angarano G.; Mutations, Salvage Study Group. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. *J Med Virol* 80(10):1695-706, 2008. (IF: 2.831).
5. Palmisano L., Giuliano M., Bucciardini R., Fragola V., Andreotti M., Galluzzo CM., Pirillo MF., Weimer LE., Arcieri R., Germinario EA., Amici R., Mancini MG., d'Arminio Monforte A., Castelli F., Caramello P., Vella S. and the Italian ISS-PART Clinical Centers. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing

repeated treatment interruptions: the Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) Study. *J Acquir Immune Defic Syndr* 46: 39-47, 2007. (IF: 4.412).

6. Puro V., De Carli G., Ippolito G. and the Italian registry of antiretroviral post-exposure prophylaxis. Postexposure HIV prophylaxis regimen. *Clin Infect Dis* 40(1):205-206, 2005. (IF:5.393).
7. Puro V., Soldani F., Cicalini S., De Carli G., Ippolito G. Hepatic safety and postexposure prophylaxis. *Clin Infect Dis* 39(7): 1083-1084, 2004. (IF:5.393).
8. Puro V., Soldani F., De Carli G., Lazarevic Z., Mattioli F., Ippolito G., on behalf of the Italian Registry of Antiretroviral Post-Exposure Prophylaxis. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. *AIDS* 17(13):1988-1990, 2003.(IF: 6.881).
9. The Genoese Group for the Study of Systemic Sclerosis. Clinical evaluation of systemic sclerosis : a comprehensive panel of diagnostic tests to asses skin, microvascular and visceral involvement. *Ann Ital Med Int* 14(2):79-85, 1999.

List of print publications in non-indexed journals

1. Cagnati P., Puppo F., Fazzuoli L., **Murdaca G.** Multiparametric endocrine evaluation of healthy subjects undergoing prolonged head down tilt bed rest anti-gravitary posture. *Journal of space exploration* 2(1), 2013.
2. **Murdaca G.**, Puppo F. Tumor Necrosis Factor (TNF)- α Gene +489 Polymorphisms: Association with Psoriatic Arthritis. *J Biol Res LXXXVI (1):38-41, 2013.*
3. Boccardo F., **Murdaca G.**, Cagnati P., Gulli R., Caiti M., Dessalvi S., Puppo F., Campisi C. Differential diagnosis in recurrent intestinal perforation: chronic inflammatory disease with intestinal lymphedema or antiphospholipid syndrome? *The European Journal of Lymphology* 23(65):20-22, 2012.
4. **Murdaca G.**, Cagnati P., Puppo F. Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment. *J Biol Res LXXXIV(1):144-147, 2011.*
5. **Murdaca G.**, Cagnati P., Puppo F. Serum Levels of Classical HLA Class I Antigen in HIV-Infected Patients During Antiretroviral Therapy. Correlation with the Clinical Outcome. *J Biol Res LXXXII (1): 88-93, 2009.*
6. **Murdaca G.**, Barabino G., Puppo F. Efficacia del trattamento con anti-TNF-alfa in una paziente affetta da granuloma annulare generalizzato. *Immune Mediated Inflammatory diseases. Case reports. Volume VI, 2007.*
7. Cagnati P., **Murdaca G.**, Colombo B.M., Puppo F. Modifications of Neuro-Endocrine Parameters Induced by Antiorthostatic Bed-Rest in Human Healthy Volunteers. *Exp Biol Rep .1: 1-11, 2007.*

8. **Coautore** di: Puro V, De Carli G, Signorini L, Pan A., Del Borgo C., Fantoni M., Orchi N., Calcagno G., Calzetti C., Franco A., Cassola G., Niero F., Raineri G., Salassa B., Vivarelli A., Irato L., Ippolito G. Registro italiano delle profilassi con antiretrovirali dopo esposizione occupazionale, sessuale o parenterale ad HIV- Aggiornamento 2003. *Giornale Italiano di Malattie Infettive* 10(Suppl 1): S154-S155, 2004.
9. Varnier OE., McDermott JL., Giri AA., Bertolotti F., Martini I., Levreri I., Giacomini M., Mora R., Mora F., Campelli A., **Murdaca G.**, Puppo F., Indiveri F. Virological markers in HIV-1 infected patients. *Minerva Ginecologica* 54(Suppl 1 al N. 6): 9-13, 2002.
10. Icardi G., **Murdaca G.**, Marasso P., Gota F., Massone L., Bacilieri S., Valle L., Tinteri C. Valutazione mediante sequenziamento virale della prevalenza di mutazioni associate a resistenza ai farmaci antiretrovirali in pazienti HIV+ naive. *Sanità e Sicurezza, supplemento speciale riferito al Tomo n. 1: 253-256*, ottobre 2002.
11. **Murdaca G.**, Indiveri F., Puppo F. Prospettive immunoterapeutiche nella infezione da HIV. *CIC Edizioni Internazionali, settembre 2002.*

List of Written Reports to Congresses

1. Ansaldi F., **Murdaca G.**, Garbarino E., Comino I., Gota F., Picasso M., Durando P., Crovari P. Single 63 codon mutation in protease region: unexpected presence in naive patients and sudden virological and immunological response, in: XIII international AIDS conference-Durban- South Africa. 9-14 July 2000. Basic science, clinical science, epidemiology prevention and public health. Monduzzi editore-international proceedings division 2000.